82 results on '"Mok, A."'
Search Results
2. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC.
- Author
-
Mok, T.S.K., Lopes, G., Cho, B.C., Kowalski, D.M., Kasahara, K., Wu, Y.-L., de Castro, G., Turna, H.Z., Cristescu, R., Aurora-Garg, D., Loboda, A., Lunceford, J., Kobie, J., Ayers, M., Pietanza, M.C., Piperdi, B., and Herbst, R.S.
- Subjects
- *
CLINICAL trials , *TREATMENT effectiveness , *NON-small-cell lung carcinoma , *PEMBROLIZUMAB , *CANCER chemotherapy - Abstract
We evaluated whether tissue tumor mutational burden (tTMB) and STK11 , KEAP1 , and KRAS mutations have clinical utility as biomarkers for pembrolizumab monotherapy versus platinum-based chemotherapy in patients with programmed death ligand 1 (PD-L1)-positive (tumor proportion score ≥1%) advanced/metastatic non-small-cell lung cancer (NSCLC) without EGFR / ALK alterations in the phase III KEYNOTE-042 trial. This retrospective exploratory analysis assessed prevalence of tTMB and STK11 , KEAP1 , and KRAS mutations determined by whole-exome sequencing of tumor tissue and matched normal DNA and their associations with outcomes in KEYNOTE-042. Clinical utility of tTMB was assessed using a prespecified cut point of 175 mutations/exome. Of 793 patients, 345 (43.5%) had tTMB ≥175 mutations/exome and 448 (56.5%) had tTMB <175 mutations/exome. No association was observed between PD-L1 expression and tTMB. Continuous tTMB score was associated with improved overall survival (OS) and progression-free survival among patients receiving pembrolizumab (Wald test, one-sided P < 0.001) but not those receiving chemotherapy (Wald test, two-sided P > 0.05). tTMB ≥175 mutations/exome was associated with improved outcomes for pembrolizumab versus chemotherapy, whereas tTMB <175 mutations/exome was not {OS: hazard ratio, 0.62 [95% confidence interval (CI) 0.48-0.80] and 1.09 (95% CI 0.88-1.36); progression-free survival: 0.75 (0.59-0.95) and 1.27 (1.04-1.55), respectively}. Improved OS [hazard ratio (95% CI)] for pembrolizumab versus chemotherapy was observed regardless of STK11 [ STK11 mutant (n = 33): 0.37 (0.16-0.86), STK11 wild-type (n = 396): 0.83 (0.65-1.05)]; KEAP1 [ KEAP1 mutant (n = 64): 0.75 (0.42-1.35), KEAP1 wild-type (n = 365): 0.78 (0.61-0.99)], or KRAS [ KRAS mutant (n = 69): 0.42 (0.22-0.81); KRAS wild-type (n = 232): 0.86 (0.63-1.18)] mutation status. tTMB with a cut point of ≥175 mutations/exome is a potential predictive biomarker for pembrolizumab monotherapy for advanced/metastatic PD-L1 tumor proportion score ≥1% NSCLC. Pembrolizumab is a standard first-line treatment in this setting regardless of STK11 , KEAP1 , or KRAS mutation status. • Pembrolizumab monotherapy is a standard first-line treatment of patients with PD-L1-positive advanced/metastatic NSCLC. • We assessed clinical utility of potential biomarkers among patients receiving pembrolizumab versus chemotherapy. • tTMB ≥175 mutations/exome was associated with improved outcomes among patients receiving pembrolizumab versus chemotherapy. • tTMB has potential clinical utility as a biomarker for pembrolizumab in first-line PD-L1-positive advanced/metastatic NSCLC. • Pembrolizumab improved overall survival versus chemotherapy regardless of STK11 , KEAP1 , or KRAS mutation status. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. 1435P Immunomodulatory effects and improved survival of PG2 plus preoperative chemoradiotherapy in patients with locally advanced esophageal cancer.
- Author
-
Mok, L-M., Huang, W-C., Lin, H-C., Chen, Y-J., Chan, M-L., Lai, Y-L., Huang, T-W., Chang, P-Y., Su, Y-F., Liu, C-Y., Hsieh, C-H., Teng, C.J., Wu, C-Y., Chung, C-S., Wang, L-S., Tsai, J-T., Yeh, C-T., and Tsai, T-H.
- Subjects
- *
ESOPHAGEAL cancer , *CHEMORADIOTHERAPY - Published
- 2024
- Full Text
- View/download PDF
4. 1349P Continuing osimertinib in combination with chemotherapy after osimertinib failure reduces CNS progression in patients with EGFR-mutated NSCLC and CNS metastases.
- Author
-
Li, M., Mok, K., Chan, L.L., Lee, K.W.C., Loong, H.H.F., Lam, K.C., Mok, F., Lau, Y.M., Chen, O., Ng, J., Lam, B., Chen, A., Wong, W., and Mok, T.S.K.
- Subjects
- *
COMBINATION drug therapy , *OSIMERTINIB , *NON-small-cell lung carcinoma , *METASTASIS - Published
- 2023
- Full Text
- View/download PDF
5. 565P Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib.
- Author
-
Li, M.S.C., Mok, K., Tsui, G., Lee, K.W.C., Lam, K.C., Loong, H.H.F., Mok, F., Chan, L.L., Yan, K., Ng, T.Y.J., Johnson, D., Lam, B., Wong, W., Chen, A., Lee, M.P., Chen, O., and Mok, T.S.K.
- Subjects
- *
OVERALL survival , *OSIMERTINIB , *EPIDERMAL growth factor receptors , *NON-small-cell lung carcinoma - Published
- 2023
- Full Text
- View/download PDF
6. 585P Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib.
- Author
-
Mok, T.S.K., Liu, G., Nyaw, S.F., Curcio, H., Cortot, A., Kam, T.Y., Descourt, R., Chik, Y.K., Cheema, P.K., Gwinnutt, J.M., Churchill, E.N., Nyborn, J., Curran, E., Yin, Y., Chong, K., Tanaka-Chambers, Y., Kretz, J., and Cadranel, J.
- Subjects
- *
NON-small-cell lung carcinoma , *INSERTION mutation , *EPIDERMAL growth factor receptors , *TREATMENT effectiveness - Published
- 2023
- Full Text
- View/download PDF
7. 1361P Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A.
- Author
-
Gadgeel, S.M., Mok, T.S.K., Peters, S., Nadal, E., Han, J-Y., Alatorre Alexander, J.A., Leighl, N., Sriuranpong, V., Pérol, M., Castro, G.D., de Marinis, F., Tan, D.S.W., Paul, S., Assaf, Z.J., MacLennan, M., Lohmann, T.O., Slade, M., Mathisen, M.S., Bhagawati-Prasad, V., and Dziadziuszko, R.
- Subjects
- *
CIRCULATING tumor DNA , *NON-small-cell lung carcinoma , *BIOMARKERS , *DNA , *TUMORS - Published
- 2023
- Full Text
- View/download PDF
8. Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.
- Author
-
Papadimitrakopoulou, V.A., Mok, T.S., Han, J.-Y., Ahn, M.-J., Delmonte, A., Ramalingam, S.S., Kim, S.W., Shepherd, F.A., Laskin, J., He, Y., Akamatsu, H., Theelen, W.S.M.E., Su, W.-C., John, T., Sebastian, M., Mann, H., Miranda, M., Laus, G., Rukazenkov, Y., and Wu, Y.-L.
- Subjects
- *
EPIDERMAL growth factor receptors , *PROTEIN-tyrosine kinase inhibitors , *NON-small-cell lung carcinoma , *CANCER patients , *CANCER treatment - Abstract
In AURA3 (NCT02151981), osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), significantly prolonged progression-free survival and improved response in patients with EGFR T790M advanced non-small-cell lung cancer (NSCLC) and progression on prior EGFR-TKI treatment. We report the final AURA3 overall survival (OS) analysis. Adult patients were randomized 2 : 1 to osimertinib (80 mg orally, once daily) or pemetrexed plus carboplatin/cisplatin (platinum–pemetrexed) intravenously, every 3 weeks (≤6 cycles). Patients could crossover to osimertinib on progression confirmed by blinded independent central review. OS and safety were secondary end points. A total of 279 patients were randomly assigned to receive osimertinib and 140 to platinum–pemetrexed (136 received treatment). At data cut-off (DCO; 15 March 2019), 188 patients (67%) receiving osimertinib versus 93 (66%) receiving platinum–pemetrexed had died. The hazard ratio (HR) for OS was 0.87 [95% confidence interval (CI) 0.67–1.12; P = 0.277]; the median OS was 26.8 months (95% CI 23.5–31.5) versus 22.5 months (95% CI 20.2–28.8) for osimertinib and platinum–pemetrexed, respectively. The estimated 24- and 36-month survival was 55% versus 43% and 37% versus 30%, respectively. After crossover adjustment, there was an HR of 0.54 (95% CI 0.18–1.6). Time to first subsequent therapy or death showed a clinically meaningful advantage toward osimertinib (HR 0.21, 95% CI 0.16–0.28; P < 0.001). At DCO, 99/136 (73%) patients in the platinum–pemetrexed arm had crossed over to osimertinib, 66/99 (67%) of whom had died. The most common adverse events possibly related to study treatment were diarrhea (32%; grade ≥3, 1%) and rash (grouped term; 32%; grade ≥3, <1%) in the osimertinib arm, versus nausea (47%; grade ≥3, 3%) in the platinum–pemetrexed arm. In patients with T790M advanced NSCLC, no statistically significant benefit in OS was observed for osimertinib versus platinum–pemetrexed, which possibly reflects the high crossover rate of patients from platinum–pemetrexed to osimertinib. ClinicalTrials.gov NCT02151981 ; https://clinicaltrials.gov/ct2/show/NCT02151981. • Median OS with osimertinib was 26.8 months versus 22.5 months with platinum–pemetrexed (HR 0.87, 95% CI 0.67–1.12; P = 0.277). • The lack of a significant survival benefit could reflect high percentage (73%) of platinum–pemetrexed to osimertinib crossover. • Analysis of OS adjusted for crossover showed an HR of 0.54 (95% CI 0.18–1.60). • Among patients receiving subsequent anticancer therapy, platinum chemotherapy was the most common after osimertinib (65%). • Grade ≥3 (possibly treatment-related) adverse events were observed less frequently with osimertinib (9% versus 34% with platinum–pemetrexed). [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
9. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
- Author
-
Mok, T., Camidge, D. R., Gadgeel, S. M., Rosell, R., Dziadziuszko, R., Kim, D.-W., Pérol, M., Ou, S.-H. I., Ahn, J. S., Shaw, A. T., Bordogna, W., Smoljanović, V., Hilton, M., Ruf, T., Noé, J., and Peters, S.
- Subjects
- *
NON-small-cell lung carcinoma , *PROGRESSION-free survival , *PROTEIN-tyrosine kinases , *CENTRAL nervous system - Abstract
Background: The ALEX study demonstrated significantly improved progression-free survival (PFS) with alectinib versus crizotinib in treatment-naive ALK-positive non-small-cell lung cancer (NSCLC) at the primary data cut-off (9 February 2017). We report mature PFS (cut-off: 30 November 2018) and overall survival (OS) data up to 5 years (cut-off: 29 November 2019). Patients and methods: Patients with stage III/IV ALK-positive NSCLC were randomized to receive twice-daily alectinib 600 mg (n = 152) or crizotinib 250 mg (n = 151) until disease progression, toxicity, withdrawal or death. Primary end point: investigator-assessed PFS. Secondary end points included objective response rate, OS and safety. Results: Mature PFS data showed significantly prolonged investigator-assessed PFS with alectinib [hazard ratio (HR) 0.43, 95% confidence interval (CI) 0.32e0.58; median PFS 34.8 versus 10.9 months crizotinib]. Median duration of OS follow-up: 48.2 months alectinib, 23.3 months crizotinib. OS data remain immature (37% of events). Median OS was not reached with alectinib versus 57.4 months with crizotinib (stratified HR 0.67, 95% CI 0.46e0.98). The 5-year OS rate was 62.5% (95% CI 54.3e70.8) with alectinib and 45.5% (95% CI 33.6e57.4) with crizotinib, with 34.9% and 8.6% of patients still on study treatment, respectively. The OS benefit of alectinib was seen in patients with central nervous system metastases at baseline [HR 0.58 (95% CI 0.34e1.00)] and those without [HR 0.76 (95% CI 0.45 e1.26)]. Median treatment duration was longer with alectinib (28.1 versus 10.8 months), and no new safety signals were observed. Conclusions: Mature PFS data from ALEX confirmed significant improvement in PFS for alectinib over crizotinib in ALKpositive NSCLC. OS data remain immature, with a higher 5-year OS rate with alectinib versus crizotinib. This is the first global randomized study to show clinically meaningful improvement in OS for a next-generation tyrosine kinase inhibitor versus crizotinib in treatment-naive ALK-positive NSCLC. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
10. VP5-2021: IMpower133: Gene expression (GE) analysis in long-term survivors (LTS) with ES-SCLC treated with first-line carboplatin and etoposide (CE) ± atezolizumab (atezo).
- Author
-
Liu, S.V., Mok, T.S.K., Mansfield, A.S., De Boer, R.H., Losonczy, G., Sugawara, S., Krzakowski, M.J., Smolin, A., Hochmair, M.J., Garassino, M.C., Gay, C.M., Heymach, J.V., Byers, L.A., McCleland, M., Nabet, B.Y., Morris, S., Adler, L., Shames, D., and Reck, M.
- Subjects
- *
GENE expression , *SMALL cell lung cancer , *CARBOPLATIN , *ETOPOSIDE , *CANCER patients - Published
- 2021
- Full Text
- View/download PDF
11. LBA4 CANOPY-N: A phase II study of canakinumab (CAN) or pembrolizumab (PEM), alone or in combination, as neoadjuvant therapy in patients (pts) with resectable stage Ib–IIIa non-small cell lung cancer (NSCLC).
- Author
-
Mok, T.S.K., Pujol, J-L., Tsuboi, M., Lee, J., Kim, E., Leonov, O., Zhang, J., Duan, J., Lobetti-Bodoni, C., Brase, J.C., Savchenko, A., and Garrido Lopez, P.
- Subjects
- *
NON-small-cell lung carcinoma , *NEOADJUVANT chemotherapy , *PEMBROLIZUMAB - Published
- 2022
- Full Text
- View/download PDF
12. LBA8 Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722.
- Author
-
Mok, T.S.K., Nakagawa, K., Park, K., Ohe, Y., Girard, N., Kim, H.R., Wu, Y-L., Gainor, J., Lee, S-H., Chiu, C-H., Sang-We, K., Cheng-Ta, Y., Liang, W., Wu, L., Lin, M-C., Samol, J., Zhang, X., Sylvester, J., Li, S., and Yang, J.C-H.
- Subjects
- *
NON-small-cell lung carcinoma , *PROTEIN-tyrosine kinase inhibitors , *NIVOLUMAB , *DISEASE progression , *EPIDERMAL growth factor receptors - Published
- 2022
- Full Text
- View/download PDF
13. 1195TiP HERTHENA-Lung02: A randomized phase III study of patritumab deruxtecan vs platinum-based chemotherapy in locally advanced or metastatic EGFR-mutated NSCLC after progression with a third-generation EGFR TKI.
- Author
-
Mok, T.S.K., Wu, Y-L., Nishio, M., Reck, M., Wu, E., Sternberg, D.W., Esker, S., and Yu, H.A.
- Subjects
- *
EPIDERMAL growth factor receptors , *NON-small-cell lung carcinoma , *CANCER chemotherapy , *METASTASIS - Published
- 2022
- Full Text
- View/download PDF
14. Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer.
- Author
-
Mok, T. S., Geater, S. L., Iannotti, N., Thongprasert, S., Spira, A., Smith, D., Lee, V., Lim, W. T., Reyderman, L., Wang, B., Gopalakrishna, P., Garzon, F., Xu, L., and Reynolds, C.
- Subjects
- *
CLINICAL trials , *ERIBULIN , *ERLOTINIB , *LUNG cancer patients , *HEALTH outcome assessment , *CANCER chemotherapy - Abstract
A phase II study investigating intercalated combinations of eribulin and erlotinib in 21- and 28-day regimens in unselected patients with previously treated advanced non-small-cell lung cancer. Combination treatment demonstrated modest activity; the addition of erlotinib did not appear to improve outcomes in an unselected population. The 28-day regimen is suitable for further investigation.Background This phase II, open-label study investigated intercalated combinations of eribulin and erlotinib in unselected patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapies. Patients and methods Eligible patients were randomized to eribulin mesylate 2.0 mg/m2 on day 1 with erlotinib 150 mg on days 2–16 (21-day regimen) or eribulin mesylate 1.4 mg/m2 on days 1 and 8 with erlotinib 150 mg on days 15–28 (28-day regimen). The primary end point was objective response rate (ORR). Results One hundred and twenty-three patients received ≥1 cycle of therapy (63, 21-day regimen; 60, 28-day regimen). ORRs were 13% [95% confidence interval (CI) 6%–24%] and 17% (95% CI 8%–29%), and disease control rates were 48% (95% CI 35%–61%) and 63% (95% CI 50%–75%) for the 21- and 28-day regimens, respectively. The median progression-free survival and overall survival were similar with both regimens. Both regimens were well tolerated with common grade ≥3 toxicities being neutropenia, asthenia/fatigue, and dyspnoea. Sequential administration of erlotinib did not interfere with the pharmacokinetic profile of eribulin. Conclusion Intercalated combination of eribulin and erlotinib demonstrated modest activity and the addition of erlotinib did not appear to improve treatment outcome in an unselected population. The 28-day regimen is suitable for further investigation. Clinicaltrials.gov identifier NCT01104155. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
15. 396P Efficacy and safety of S-1 in elderly patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy: A subgroup analysis of the EAST-LC.
- Author
-
Yang, J.C-H., Mok, T.S.K., Lu, S., Nakagawa, K., Yamamoto, N., Shi, Y-K., Zhang, L., Soo, R.A., Morita, S., and Tamura, T.
- Subjects
- *
NON-small-cell lung carcinoma , *GERIATRIC oncology , *CANCER chemotherapy - Published
- 2020
- Full Text
- View/download PDF
16. 1293P IMpower150: Updated efficacy analysis in patients with EGFR mutations.
- Author
-
Reck, M., Mok, T., Socinski, M.A., Jotte, R.M., Lim, D.W-T., Cappuzzo, F., Orlandi, F.J., Stroyakovskiy, D., Nogami, N., Rodriguez-Abreu, D., Moro-Sibilot, D., Thomas, C.A., Barlesi, F., Finley, G., Shankar, G., Yu, W., Merritt, D., and Nishio, M.
- Subjects
- *
EPIDERMAL growth factor receptors , *PATIENTS - Published
- 2020
- Full Text
- View/download PDF
17. LBA19Updated overall survival (OS) from extended follow up in ARCHER 1050: A randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts) with EGFR mutations.
- Author
-
Mok, T S K, Cheng, Y, Zhou, X, Lee, K H, Nakagawa, K, Niho, S, Linke, R, Rosell, R, Corral, J, Migliorino, M R, Pluzanski, A, Noonan, K, Tang, Y, Wilner, K D, and Wu, Y-L
- Subjects
- *
EPIDERMAL growth factor receptors , *EPIDERMAL growth factor , *NON-small-cell lung carcinoma , *DELETION mutation , *PART-time employment - Abstract
Background The ongoing phase III ARCHER 1050 study (NCT01774721) compared dacomitinib (daco) with gefitinib (gef) as first-line therapy for pts with advanced epidermal growth factor receptor-positive (EGFR+) non-small cell lung cancer (NSCLC). Progression-free survival, duration of response, and OS significantly improved with daco vs gef. The improvement in OS was previously reported after median follow-up of 31.3 months (mo) with 220 (48.7%) total deaths. Here, final OS results are reported after a median follow-up of 47.9 mo in ARCHER 1050 to evaluate the persistence of OS improvement with daco. Methods Pts with newly diagnosed EGFR+ NSCLC were randomized 1:1 to daco or gef. Randomization was stratified by race and EGFR mutation type. Results Over a median follow-up of 47.9 mo as of 13 May 2019, 285 deaths occurred (133 [58.6%] in the daco arm [n = 227] and 152 [67.6%] in the gef arm [n = 225]). OS was still significantly improved with daco vs gef (stratified hazard ratio [HR], 0.748; 95% confidence interval [CI], 0.591–0.947; 2-sided P = 0.0155). Median OS (95% CI) with daco was 34.1 mo (29.5–39.8) vs 27.0 mo (24.4–31.6) with gef. OS30 was 56.4% with daco and 45.7% with gef. Median OS, unstratified HR, and P values for interaction are also reported by race and EGFR mutation type (Table). Dose reductions occurred in 154 (67.8%) pts receiving daco; median OS (95% CI) in pts with and without dose reductions was 42.5 (36.7–not estimable [NE]) and 20.7 (15.4–25.6) mo, respectively. In pts reduced to a lowest daco dose of 30 mg (n = 89) and 15 mg (n = 65), median OS was 36.7 mo (28.8–44.7) and NE (40.1 mo–NE), respectively. Conclusions With extended follow-up (median 47.9 mo), daco continues to improve OS over gef in pts with advanced EGFR+ NSCLC; the same trend was observed in most subgroups defined by race and EGFR status. The benefit of OS was maintained in patients who received dose reductions. Table: LBA19 Overall survival by demographics (ITT population) Events/N (%) Median a (month) HR (95% CI) (Unstratified) P b Daco Gef Daco Gef Overall 133/227 (58.6) 152/225 (67.6) 34.1 27.0 0.775 (0.614–0.978) Race per CRF Asian Mainland Chinese Japanese other East Asian Non-Asian 95/170 (55.9) 69/114 (60.5) 22/40 (55.0) 4/16 (25.0) 38/57 (66.7) 115/176 (65.3) 87/117 (74.4) 22/41 (53.7) 6/18 (33.3) 37/49 (75.5) 37.7 32.5 42.2 NE 29.5 29.1 24.9 44.8 NE 20.6 0.759 (0.578–0.996) 0.687 (0.501–0.943) 0.985 (0.546–1.780) 0.787 (0.222–2.791) 0.758 (0.480–1.196) 0.9886 c EGFR at randomization Exon 19 deletion Exon 21 L858R substitution mutation 73/134 (54.5) 60/93 (64.5) 82/133 (61.7) 70/92 (76.1) 36.7 32.5 30.8 23.2 0.847 (0.618, 1.161) 0.665 (0.470, 0.941) 0.3292 Events/N (%) Median a (month) HR (95% CI) (Unstratified) P b Daco Gef Daco Gef Overall 133/227 (58.6) 152/225 (67.6) 34.1 27.0 0.775 (0.614–0.978) Race per CRF Asian Mainland Chinese Japanese other East Asian Non-Asian 95/170 (55.9) 69/114 (60.5) 22/40 (55.0) 4/16 (25.0) 38/57 (66.7) 115/176 (65.3) 87/117 (74.4) 22/41 (53.7) 6/18 (33.3) 37/49 (75.5) 37.7 32.5 42.2 NE 29.5 29.1 24.9 44.8 NE 20.6 0.759 (0.578–0.996) 0.687 (0.501–0.943) 0.985 (0.546–1.780) 0.787 (0.222–2.791) 0.758 (0.480–1.196) 0.9886 c EGFR at randomization Exon 19 deletion Exon 21 L858R substitution mutation 73/134 (54.5) 60/93 (64.5) 82/133 (61.7) 70/92 (76.1) 36.7 32.5 30.8 23.2 0.847 (0.618, 1.161) 0.665 (0.470, 0.941) 0.3292 a Kaplan-Meier estimate; b P interaction; c P for interaction of treatment by Asian vs non-Asian CI, confidence interval; CRF, case report form; daco, dacomitinib; ECOG PS, Eastern Cooperative Oncology Group Performance Status; EGFR, epidermal growth factor receptor; gef, gefitinib; HR, Hazard ratio; ITT, intention-to-treat, NE, not estimable. Table: LBA19 Overall survival by demographics (ITT population) Events/N (%) Median a (month) HR (95% CI) (Unstratified) P b Daco Gef Daco Gef Overall 133/227 (58.6) 152/225 (67.6) 34.1 27.0 0.775 (0.614–0.978) Race per CRF Asian Mainland Chinese Japanese other East Asian Non-Asian 95/170 (55.9) 69/114 (60.5) 22/40 (55.0) 4/16 (25.0) 38/57 (66.7) 115/176 (65.3) 87/117 (74.4) 22/41 (53.7) 6/18 (33.3) 37/49 (75.5) 37.7 32.5 42.2 NE 29.5 29.1 24.9 44.8 NE 20.6 0.759 (0.578–0.996) 0.687 (0.501–0.943) 0.985 (0.546–1.780) 0.787 (0.222–2.791) 0.758 (0.480–1.196) 0.9886 c EGFR at randomization Exon 19 deletion Exon 21 L858R substitution mutation 73/134 (54.5) 60/93 (64.5) 82/133 (61.7) 70/92 (76.1) 36.7 32.5 30.8 23.2 0.847 (0.618, 1.161) 0.665 (0.470, 0.941) 0.3292 Events/N (%) Median a (month) HR (95% CI) (Unstratified) P b Daco Gef Daco Gef Overall 133/227 (58.6) 152/225 (67.6) 34.1 27.0 0.775 (0.614–0.978) Race per CRF Asian Mainland Chinese Japanese other East Asian Non-Asian 95/170 (55.9) 69/114 (60.5) 22/40 (55.0) 4/16 (25.0) 38/57 (66.7) 115/176 (65.3) 87/117 (74.4) 22/41 (53.7) 6/18 (33.3) 37/49 (75.5) 37.7 32.5 42.2 NE 29.5 29.1 24.9 44.8 NE 20.6 0.759 (0.578–0.996) 0.687 (0.501–0.943) 0.985 (0.546–1.780) 0.787 (0.222–2.791) 0.758 (0.480–1.196) 0.9886 c EGFR at randomization Exon 19 deletion Exon 21 L858R substitution mutation 73/134 (54.5) 60/93 (64.5) 82/133 (61.7) 70/92 (76.1) 36.7 32.5 30.8 23.2 0.847 (0.618, 1.161) 0.665 (0.470, 0.941) 0.3292 a Kaplan-Meier estimate; b P interaction; c P for interaction of treatment by Asian vs non-Asian CI, confidence interval; CRF, case report form; daco, dacomitinib; ECOG PS, Eastern Cooperative Oncology Group Performance Status; EGFR, epidermal growth factor receptor; gef, gefitinib; HR, Hazard ratio; ITT, intention-to-treat, NE, not estimable. Clinical trial identification NCT01774721. Editorial acknowledgement Jessica Yuan (inScience Communications, Springer Healthcare, New York, NY, USA). Legal entity responsible for the study Pfizer Inc. Funding Pfizer Inc. and SFJ Pharmaceuticals® Disclosure T.S.K. Mok: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: ACEA Pharma; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Alpha Biopharma Co. Ltd.; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Amgen; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Amoy Diagnostics Co. Ltd.; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, before 1/1/19: AstraZeneca ; Honoraria (self), Advisory / Consultancy: Bayer; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: BI; Honoraria (self), Advisory / Consultancy: Blueprint Medicines Corporation; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): BMS; Honoraria (self), Advisory / Consultancy: Celgene; Honoraria (self), Advisory / Consultancy: CStone Pharmaceuticals; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Eli Lilly; Honoraria (self), Advisory / Consultancy: Fishawack Facilitate Ltd; Honoraria (self), Advisory / Consultancy: Hengrui Therapeutics Inc.; Honoraria (self), Advisory / Consultancy: Ignyta, Inc.; Honoraria (self), Advisory / Consultancy, Sept 2019: Incyte Corporation; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: InMed Medical Communication; Honoraria (self), Advisory / Consultancy, Jun 2019: Iqvia; Honoraria (self), Advisory / Consultancy: Janssen; Honoraria (self), Advisory / Consultancy: Loxo-Oncology; Honoraria (self), Advisory / Consultancy: Merck Serono; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): MSD; Honoraria (self), Advisory / Consultancy: MoreHealth; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Novartis; Honoraria (self), Advisory / Consultancy: OncoGenex Pharmaceuticals, Inc.; Honoraria (self), Advisory / Consultancy: OrigiMed; Honoraria (self), Advisory / Consultancy: PeerVoice; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Pfizer; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: PrIME Oncology; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche/Genentech; Honoraria (self), Advisory / Consultancy: Sanofi-Aventis R&D; Honoraria (self), Advisory / Consultancy: SFJ Pharmaceutical Ltd.; Honoraria (self), Advisory / Consultancy: Takeda Pharmaceuticals HK Ltd.; Honoraria (self), Advisory / Consultancy: Vertex Pharmaceuticals; Honoraria (self), Advisory / Consultancy: Yuhan Corporation; Advisory / Consultancy: Cirina; Advisory / Consultancy, uncompensated: GeneDecode Co. Ltd.; Speaker Bureau / Expert testimony: Taiho; Speaker Bureau / Expert testimony: Takeda Oncology; Leadership role, Officer / Board of Directors, Remunerated: AstraZeneca PLC; Leadership role, Officer / Board of Directors, Remunerated: Hutchison Chi-Med; Leadership role, Officer / Board of Directors, Non-remunerated: American Society of Clinical Oncology; Leadership role, Officer / Board of Directors, Non-remunerated: Asian Thoracic Oncology Research Group ; Leadership role, Officer / Board of Directors, Non-remunerated: Chinese Lung Cancer Research Foundation Limited; Leadership role, Officer / Board of Directors, Non-remunerated: Chinese Society of Clinical Oncology; Leadership role, Officer / Board of Directors, Non-remunerated: Hong Kong Cancer Fund; Leadership role, Officer / Board of Directors, Non-remunerated: Hong Kong Cancer Therapy Society ; Leadership role, Officer / Board of Directors, term ended on 30/4/19: International Association for the Study of Lung Cancer ; Research grant / Funding (institution): Clovis Oncology; Research grant / Funding (institution): Roche; Research grant / Funding (institution): SFJ; Research grant / Funding (institution): XCovery; Shareholder / Stockholder / Stock options, Shareholder: Hutchison Chi-Med; Shareholder / Stockholder / Stock options, Shareholder: Sanomics Ltd.; Shareholder / Stockholder / Stock options, now Biolidics Ltd.; Stock option: Clearbridge Biomedics; Shareholder / Stockholder / Stock options, Stock option: Loxo-Oncology; Shareholder / Stockholder / Stock options, Stock option: OrigiMed Co. Ltd.; Shareholder / Stockholder / Stock options, Stock option: Virtus Medical Group; Research grant / Funding (institution): AstraZeneca. K.H. Lee: Advisory / Consultancy: MSD; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: BMS. K. Nakagawa: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Astellas Pharma Inc.; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Takeda Pharmaceutical Co. Ltd; Honoraria (self), Research grant / Funding (institution): AstraZeneca K.K.; Honoraria (self), Research grant / Funding (institution): Chugai Pharmaceutical Co. Ltd.; Honoraria (self), Research grant / Funding (institution): MSD K.K.; Honoraria (self), Research grant / Funding (institution): Eli Lilly Japan K.K.; Honoraria (self), Research grant / Funding (institution): Ono Pharmaceutical Co. Ltd.; Honoraria (self), Research grant / Funding (institution): Nippon Boehringer Ingelheim Co. Ltd.; Honoraria (self), Research grant / Funding (institution): Daiichi Sankyo Co. Ltd.; Honoraria (self), Research grant / Funding (institution): Novartis Pharma K.K.; Honoraria (self), Research grant / Funding (institution): Taiho Pharmaceutical Co. Ltd.; Honoraria (self), Research grant / Funding (institution): Pfizer Japan Inc.; Honoraria (self), Research grant / Funding (institution): Bristol-Myers Squibb Company; Honoraria (self): Nikkei Business Publications, Inc.; Honoraria (self): Kyorin Pharmaceutical Co. Ltd.; Honoraria (self): Medicus Shuppan, Publishers Co. Ltd.; Honoraria (self): CareNet, Inc; Honoraria (self): Thermo Fisher Scientific K.K.; Honoraria (self): Nichi-Iko Pharmaceutical Co. Ltd.; Honoraria (self): Nanzando Co. Ltd; Honoraria (self): Hisamitsu Pharmaceutical Co. Inc; Honoraria (self): Medical Review Co. Ltd.; Honoraria (self): Yodosha Co. Ltd; Honoraria (self): Yomiuri Telecasting Corporation; Research grant / Funding (institution): Icon Japan K.K.; Research grant / Funding (institution): Quintiles Inc.; Research grant / Funding (institution): CMIC Shift Zero K.K.; Research grant / Funding (institution): Eisai Co. Ltd.; Research grant / Funding (institution): Parexel International Corp.; Research grant / Funding (institution): Kissei Pharmaceutical Co. Ltd.; Research grant / Funding (institution): Iqvia; Research grant / Funding (institution): Kyowa Hakko Kirin Co. Ltd; Research grant / Funding (institution): EPS Corporation; Research grant / Funding (institution): SymBio Pharmaceuticals Limited; Research grant / Funding (institution): Bayer Yakuhin, Ltd; Research grant / Funding (institution): Merck Serono Co. Ltd.; Research grant / Funding (institution): A2 Healthcare Corp.; Research grant / Funding (institution): AbbVie Inc.. S. Niho: Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self): Chugai; Honoraria (self): Taiho; Honoraria (self), Research grant / Funding (institution): MSD; Honoraria (self): Bristol-Myers Squibb; Honoraria (self), Research grant / Funding (institution): Eli Lilly; Honoraria (self): Novartis; Honoraria (self): Boehringer Ingelheim; Research grant / Funding (institution): Merck Serono. R. Linke: Full / Part-time employment: SFJ Pharmaceuticals®. M.R. Migliorino: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: MSD; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: BI; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: BMS; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche. A. Pluzanski: Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony: Boehringer Ingelheim; Advisory / Consultancy, Speaker Bureau / Expert testimony: Bristol-Myers Squibb; Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck Sharp & Dohme; Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche. K. Noonan: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer. Y. Tang: Full / Part-time employment: Pfizer Inc. K.D. Wilner: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer Inc. Y. Wu: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Roche; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Boehringer Ingelheim; Honoraria (self): Eli Lilly; Honoraria (self): Pfizer; Honoraria (self): MSD; Honoraria (self): BMS. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
18. 480PSafety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050.
- Author
-
Mok, T S K, Cheng, Y, Zhou, X, Lee, K H, Nakagawa, K, Niho, S, Rosell, R, Linke, R, Wong, C H, Tang, Y, Singh, M, Wilner, K D, and Wu, Y-L
- Subjects
- *
PROGRESSION-free survival , *PART-time employment - Abstract
Background In the ongoing phase 3 comparison of dacomitinib (daco) and gefitinib (gef) (ARCHER 1050; NCT01774721) as first-line therapy for EGFR-mutation-positive (EGFR+) advanced NSCLC, daco was associated with significant improvement in progression free survival (PFS) and overall survival (OS). Here we present results for the subset of Asian patients (pts). Methods Eligible pts with newly diagnosed stage IIIB/IV or recurrent EGFR+ advanced NSCLC were randomized (1:1) to oral daco 45 mg once daily or gef 250 mg. Randomization was stratified by race and EGFR mutation (exon 19 del/exon 21 L858R) status. The primary efficacy endpoint was PFS by blinded independent radiologic central review (BIRC). Secondary endpoints were OS, objective response rate (ORR) and duration of response (DOR) by BIRC, and safety. Results Of 346 Asian pts, 170 were randomized to daco treatment and 176 to gef. Demographics and baseline characteristics of the groups were well balanced. At the July 29, 2016 data cutoff, the hazard ratio for PFS was 0.510 (95% confidence interval [CI] 0.392, 0.664), favoring daco (2-sided p value < 0.0001). Median PFS was 16.5 months (95% CI 12.9, 18.4) for daco and 9.3 months for gef (95% CI 9.2, 11.0). OS, ORR and DOR are shown in the table. Treatment-related adverse events (TRAEs) occurring in ≥ 50% of daco-treated pts were diarrhea (88.2%), paronychia (64.7%), and dermatitis acneiform (56.5%). In the gef arm, diarrhea (52.3%) was the only TRAE that occurred in ≥ 50% of pts. The daco dose was reduced in 67.6% of pts associated with adverse events (AEs); gef dose was reduced to every other day dosing in 9.7% of pts associated with AEs. Conclusions First-line daco was associated with significant prolongation of PFS compared with gef in Asian pts with EGFR+ advanced NSCLC. Daco treatment showed improved OS, ORR, and DOR compared to gef treatment. The AE profile for daco and gef in Asian pts was consistent with the overall ARCHER 1050 study. Table: 480P Key secondary endpoints Dacomitinib N = 170 Gefitinib N = 176 Median overall survival, months (95% CI) a 34.2 (30.1, NE 29.1 (25.2,NE) Objective response rate, % (95% CI) 77.1 (70.0, 83.1) 72.7 (65.5, 79.2) ---Patients with complete response (n, %) 9 (5.3) 4 (2.3) ---Patients with partial response (n, %) 122 (71.8) 124 (70.5) Median duration of response, months (95% CI) 16.6 (13.8, 30.4) 8.3 (8.1, 10.2) Dacomitinib N = 170 Gefitinib N = 176 Median overall survival, months (95% CI) a 34.2 (30.1, NE 29.1 (25.2,NE) Objective response rate, % (95% CI) 77.1 (70.0, 83.1) 72.7 (65.5, 79.2) ---Patients with complete response (n, %) 9 (5.3) 4 (2.3) ---Patients with partial response (n, %) 122 (71.8) 124 (70.5) Median duration of response, months (95% CI) 16.6 (13.8, 30.4) 8.3 (8.1, 10.2) CI, confidence interval; N/n;number of patients; NE; not estimable. a Feb 17, 2017 was the data cutoff for final OS analysis. Table: 480P Key secondary endpoints Dacomitinib N = 170 Gefitinib N = 176 Median overall survival, months (95% CI) a 34.2 (30.1, NE 29.1 (25.2,NE) Objective response rate, % (95% CI) 77.1 (70.0, 83.1) 72.7 (65.5, 79.2) ---Patients with complete response (n, %) 9 (5.3) 4 (2.3) ---Patients with partial response (n, %) 122 (71.8) 124 (70.5) Median duration of response, months (95% CI) 16.6 (13.8, 30.4) 8.3 (8.1, 10.2) Dacomitinib N = 170 Gefitinib N = 176 Median overall survival, months (95% CI) a 34.2 (30.1, NE 29.1 (25.2,NE) Objective response rate, % (95% CI) 77.1 (70.0, 83.1) 72.7 (65.5, 79.2) ---Patients with complete response (n, %) 9 (5.3) 4 (2.3) ---Patients with partial response (n, %) 122 (71.8) 124 (70.5) Median duration of response, months (95% CI) 16.6 (13.8, 30.4) 8.3 (8.1, 10.2) CI, confidence interval; N/n;number of patients; NE; not estimable. a Feb 17, 2017 was the data cutoff for final OS analysis. Clinical trial identification NCT01774721. Editorial acknowledgement Medical writing support was provided by Michelle Daniels (inScience Communications, Springer Healthcare, Philadelphia, PA, USA). Legal entity responsible for the study Pfizer Inc. Funding Pfizer Inc. Disclosure T.S.K. Mok: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: ACEA Pharma; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Alpha Biopharma Co. Ltd.; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Amgen; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Amoy Diagnostics Co. LTD.; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, before 1/1/19: AstraZeneca; Honoraria (self), Advisory / Consultancy: Bayer; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: BI; Honoraria (self), Advisory / Consultancy: Blueprint Medicines Corporation; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): BMS; Honoraria (self), Advisory / Consultancy: Celgene; Honoraria (self), Advisory / Consultancy: CStone Pharmaceuticals; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Eli Lilly; Honoraria (self), Advisory / Consultancy: Fishawack Facilitate Ltd; Honoraria (self), Advisory / Consultancy: Hengrui Therapeutics Inc.; Honoraria (self), Advisory / Consultancy: Ignyta, Inc.; Honoraria (self), Advisory / Consultancy, Sept 2019: Incyte Corporation; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: InMed Medical Communication; Honoraria (self), Advisory / Consultancy, Jun 2019: IQVIA; Honoraria (self), Advisory / Consultancy: Janssen; Honoraria (self), Advisory / Consultancy: Loxo-Oncology; Honoraria (self), Advisory / Consultancy: Merck Serono; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): MSD; Honoraria (self), Advisory / Consultancy: MoreHealth; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Novartis; Honoraria (self), Advisory / Consultancy: OncoGenex Pharmaceuticals, Inc.; Honoraria (self), Advisory / Consultancy: OrigiMed; Honoraria (self), Advisory / Consultancy: PeerVoice; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Pfizer; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: PrIME Oncology; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche/Genentech; Honoraria (self), Advisory / Consultancy: Sanofi-Aventis R&D; Honoraria (self), Advisory / Consultancy: SFJ Pharmaceutical Ltd.; Honoraria (self), Advisory / Consultancy: Takeda Pharmaceuticals HK Ltd.; Honoraria (self), Advisory / Consultancy: Vertex Pharmaceuticals; Honoraria (self), Advisory / Consultancy: Yuhan Corporation; Advisory / Consultancy: Cirina; Advisory / Consultancy, uncompensated: geneDecode Co. Ltd.; Speaker Bureau / Expert testimony: Taiho; Speaker Bureau / Expert testimony: Takeda Oncology; Leadership role, Officer / Board of Directors, Remunerated: AstraZeneca PLC; Leadership role, Officer / Board of Directors, Remunerated: Hutchison Chi-Med; Leadership role, Officer / Board of Directors, Non-remunerated: American Society of Clinical Oncology; Leadership role, Officer / Board of Directors, Non-remunerated: Asian Thoracic Oncology Research Group; Leadership role, Officer / Board of Directors, Non-remunerated: Chinese Lung Cancer Research Foundation Limited; Leadership role, Officer / Board of Directors, Non-remunerated: Chinese Society of Clinical Oncology; Leadership role, Officer / Board of Directors, Non-remunerated: Hong Kong Cancer Fund; Leadership role, Officer / Board of Directors, Non-remunerated: Hong Kong Cancer Therapy Society; Leadership role, Officer / Board of Directors, term ended on 30/4/19: International Association for the Study of Lung Cancer ; Research grant / Funding (institution): Clovis Oncology; Research grant / Funding (institution): Roche; Research grant / Funding (institution): SFJ; Research grant / Funding (institution): XCovery; Shareholder / Stockholder / Stock options, Shareholder: Hutchison Chi-Med; Shareholder / Stockholder / Stock options, Shareholder: Sanomics Ltd.; Shareholder / Stockholder / Stock options, now Biolidics Ltd.; Stock option: Clearbridge Biomedics; Shareholder / Stockholder / Stock options, Stock option: Loxo-Oncology; Shareholder / Stockholder / Stock options, Stock option: OrigiMed Co. Ltd.; Shareholder / Stockholder / Stock options, Stock option: Virtus Medical Group; Research grant / Funding (institution): AstraZeneca. K.H. Lee: Advisory / Consultancy: MSD; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: BMS. K. Nakagawa: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Astellas Pharma Inc.; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Takeda Pharmaceutical Co. Ltd; Honoraria (self), Research grant / Funding (institution): AstraZeneca K.K.; Honoraria (self), Research grant / Funding (institution): Chugai Pharmaceutical Co.Ltd.; Honoraria (self), Research grant / Funding (institution): MSD K.K.; Honoraria (self), Research grant / Funding (institution): Eli Lilly Japan K.K.; Honoraria (self), Research grant / Funding (institution): Ono Pharmaceutical Co. Ltd.; Honoraria (self), Research grant / Funding (institution): Nippon Boehringer Ingelheim Co. Ltd.; Honoraria (self), Research grant / Funding (institution): Daiichi Sankyo Co. Ltd.; Honoraria (self), Research grant / Funding (institution): Novartis Pharma K.K.; Honoraria (self), Research grant / Funding (institution): Taiho Pharmaceutical Co. Ltd.; Honoraria (self), Research grant / Funding (institution): Pfizer Japan Inc.; Honoraria (self), Research grant / Funding (institution): Bristol-Myers Squibb; Honoraria (self): Nikkei Business Publications, Inc.; Honoraria (self): Kyorin Pharmaceutical Co. Ltd.; Honoraria (self): Medicus Shuppan, Publishers Co. Ltd.; Honoraria (self): CareNet, Inc.; Honoraria (self): Thermo Fisher Scientific K.K.; Honoraria (self): Nichi-Iko Pharmaceutical Co. Ltd.; Honoraria (self): Nanzando Co. Ltd; Honoraria (self): Hisamitsu Pharmaceutical Co. Inc; Honoraria (self): Medical Review Co. Ltd.; Honoraria (self): Yodosha Co. Ltd; Honoraria (self): Yomiuri Telecasting Corporation; Research grant / Funding (institution): ICON Japan K.K.; Research grant / Funding (institution): Quintiles Inc.; Research grant / Funding (institution): CMIC Shift Zero K.K.; Research grant / Funding (institution): Eisai Co. Ltd.; Research grant / Funding (institution): Parexel International Corp.; Research grant / Funding (institution): Kissei Pharmaceutical Co. Ltd.; Research grant / Funding (institution): IQVIA; Research grant / Funding (institution): Kyowa Hakko Kirin Co. Ltd; Research grant / Funding (institution): EPS Corporation; Research grant / Funding (institution): SymBio Pharmaceuticals Limited; Research grant / Funding (institution): Bayer Yakuhin, Ltd; Research grant / Funding (institution): Merck Serono Co. Ltd.; Research grant / Funding (institution): A2 Healthcare Corp.; Research grant / Funding (institution): AbbVie Inc.. S. Niho: Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self): Chugai; Honoraria (self): Taiho; Honoraria (self), Research grant / Funding (institution): MSD; Honoraria (self): Bristol-Myers Squibb; Honoraria (self), Research grant / Funding (institution): Eli Lilly; Honoraria (self): Novartis; Honoraria (self): Boehringer Ingelheim; Research grant / Funding (institution): Merck Serono. R. Linke: Full / Part-time employment: SFJ Pharmaceuticals®. C.H. Wong: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer. Y. Tang: Full / Part-time employment: Pfizer Inc. M. Singh: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer. K.D. Wilner: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer Inc. Y-L. Wu: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Roche; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Boehringer Ingelheim; Honoraria (self): Eli Lilly; Honoraria (self): Pfizer; Honoraria (self): MSD; Honoraria (self): BMS. All other authors have declared no conflicts of interest. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
19. 475OOverall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI).
- Author
-
Wu, Y-L, Mok, T S K, Han, J-Y, Ahn, M-J, Delmonte, A, Ramalingam, S S, Kim, S-W, Shepherd, F A, Laskin, J, He, Y, Akamatsu, H, Theelen, W S M E, Su, W-C, John, T, Sebastian, M, Mann, H, Miranda, M, Laus, G, Rukazenkov, Y, and Papadimitrakopoulou, V
- Subjects
- *
NON-small-cell lung carcinoma , *KINASE inhibitors , *PART-time employment , *STOCK options , *BODY surface area - Abstract
Background In AURA3 (NCT02151981), osimertinib, a 3rd-generation EGFR-TKI, significantly prolonged progressionfree survival (PFS) and improved response rate vs plt-pem in pts with centrally confirmed EGFR T790M advanced NSCLC and progression on a prior EGFR-TKI. Here we report mature OS data. Methods Adult pts were randomised 2:1 to receive oral osimertinib (80 mg once daily) or intravenous pem (500 mg per m2 of body surface area) + carboplatin (target area under the curve 5)/cisplatin (75 mg per m2), every 3 weeks, ≤6 cycles. Treatment beyond progression (RECIST 1.1) was allowed if clinical benefit continued. Pts receiving plt-pem could cross over to osimertinib on disease progression. Asymptomatic CNS metastases were allowed. Primary endpoint was investigator-assessed PFS. OS and safety are reported as secondary endpoints. Data cut-off (DCO): 15 March 2019. Results In total, 419 pts were randomised (osimertinib, n = 279; plt-pem, n = 140); 99 pts (71%) crossed over to osimertinib from plt-pem. At DCO, 188 pts (67%) in the osimertinib arm vs 93 pts (66%) in the plt-pem arm had died, including 66/99 (67%) crossover pts; median OS 26.8 mo (95% confidence interval [CI] 23.5, 31.5) vs 22.5 mo (95% CI 20.2, 28.8) respectively, hazard ratio (HR) 0.87 (95% CI 0.67, 1.12; p = 0.277); survival rate at 24 mo was 55% vs 43% and at 36 mo was 37% vs 30%. Time to first subsequent treatment showed a large, clinically meaningful numerical advantage towards osimertinib, HR 0.21 (95% CI 0.16, 0.28; p < 0.001); time to second subsequent treatment, HR 0.87 (95% CI 0.69, 1.11; p = 0.263). In both arms, 99% pts had any adverse event (AE). Any AE grade ≥3 causally related to study treatment was 9% vs 34% for osimertinib and plt-pem respectively. Most common AEs were diarrhoea, 44% (grade ≥3, 1%), and nausea, 49% (grade ≥3, 4%), with osimertinib and plt-pem respectively. Conclusions A numerical advantage in OS was observed for pts receiving osimertinib vs plt-pem, with the majority of pts in the plt-pem arm having crossed over to osimertinib. The safety profile of osimertinib remains consistent with previous findings. Clinical trial identification NCT02151981. Editorial acknowledgement Laura Crocker, BMedSci, of iMed Comms, an Ashfield Company, who provided medical writing support funded by AstraZeneca. Legal entity responsible for the study AstraZeneca. Funding AstraZeneca. Disclosure Y-L. Wu: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Roche; Honoraria (self): Eli Lilly; Honoraria (self): Pfizer; Honoraria (self): MSD; Honoraria (self): Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy: Boehringer Ingelheim. T.S.K. Mok: Honoraria (self): ACEA Pharma, Alpha Biopharma Co. Ltd. Amgen, Amoy Diagnostics Co. LTD. AstraZeneca (before 1/1/19), Bayer, BI, Blueprint Medicines Corporation, BMS, Celgene, CStone Pharmaceuticals, Eli Lilly, Fishawack Facilitate Ltd, Hengrui Therapeutics Inc. Ignyt; Advisory / Consultancy: ACEA Pharma, Alpha Biopharma Co. Ltd. Amgen, Amoy Diagnostics Co. LTD. AstraZeneca (before 1/1/19), Bayer, BI, Blueprint Medicines Corporation, BMS, Celgene, Cirina, CStone Pharmaceuticals, Eli Lilly, Fishawack Facilitate Ltd, geneDecode Co. Ltd. (un; Leadership role: AstraZeneca PLC, Hutchison Chi-Med; Research grant / Funding (institution): AstraZeneca, BMS, Clovis Oncology, MSD, Novartis, Pfizer, Roche, SFJ, XCovery; Shareholder / Stockholder / Stock options: Shareholder: Hutchison Chi-Med, Sanomics Ltd. Stock option: Clearbridge Biomedics (now Biolidics Ltd.), Loxo-Oncology, OrigiMed Co. Ltd. Virtus Medical Group; Full / Part-time employment: The Chinese University of Hong Kong; Officer / Board of Directors: Remunerated: AstraZeneca PLC, Hutchison Chi-Med Non-remunerated: American Society of Clinical Oncology (ASCO) Asian Thoracic Oncology Research Group (ATORG) Chinese Lung Cancer Research Foundation Limited (CLCRF) Chinese Society of Clinical Oncology (CS. J-Y. Han: Honoraria (self): Roche, AstraZeneca, Bristol-Myers Squibb, MSD, Takeda; Advisory / Consultancy: AstraZeneca, Bristol-Myers Squibb, MSD, Takeda, Pfizer, Novartis, Lilly; Research grant / Funding (self): Roche, Pfizer, Ono Pharmaceutical, Takeda. M-J. Ahn: Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca, Merck, Sharp & Dohme, Ono Pharmaceutical, Lilly, Roche; Advisory / Consultancy: Alpha Pharmaceutical, Takeda. S.S. Ramalingam: Honoraria (self), Advisory / Consultancy: AstraZeneca, Amgen, Bristol-Myers Squibb, Merck, Roche/Genentech, Loxo, Nektar, Tesaro; Research grant / Funding (institution): AstraZeneca, Amgen, Bristol-Myers Squibb, Merck, Tesaro, Advaxis, Takeda. S-W. Kim: Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca. F.A. Shepherd: Advisory / Consultancy, Research grant / Funding (institution), Shareholder / Stockholder / Stock options: AstraZeneca. J. Laskin: Research grant / Funding (institution): AstraZeneca, Roche, Boehringer Ingelheim, Pfizer; Honoraria (self): AstraZeneca, Roche, Pfizer. H. Akamatsu: Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Honoraria (institution): Chugai; Honoraria (self), Honoraria (institution), Advisory / Consultancy: Pfizer; Honoraria (self), Honoraria (institution): Boehringer Ingelheim. W-C. Su: Travel / Accommodation / Expenses: Bristol-Myers Squibb; Travel / Accommodation / Expenses: Boehringer Ingelheim. T. John: Advisory / Consultancy: Roche, Bristol-Myers Squibb, Merck, Ignyta, AstraZeneca, Takeda, Boehringer Ingelheim, Pfizer. M. Sebastian: Honoraria (self), Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca, Roche, Novartis; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Pfizer, Boehringer Ingelheim, Celgene, Takeda, Bristol-Myers Squibb, MSD; Honoraria (self), Advisory / Consultancy: Lilly. H. Mann: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. M. Miranda: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. G. Laus: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. Y. Rukazenkov: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. V. Papadimitrakopoulou: Honoraria (self): F Hoffman-La Roche; Advisory / Consultancy: Nektar Therapeutics, AstraZeneca Pharmaceuticals, Arrys Therapeutics, Merck&Co, LOXO Oncology, Araxes Pharma, F.Hoffman-LaRoche Ltd, Janssen Research Foundation, Bristol-Myers Squibb, Clovis Oncology, Eli Lilly &Co, Novartis Pharmaceuticals Corp. Takeda ; Research grant / Funding (institution): Eli Lilly &Co, Novartis, Merck, AstraZeneca Pharmaceuticals, F Hoffman-La Roche, Nektar Therapeutics, Janssen, Bristol-Myers Squibb, Checkmate, Incyte. All other authors have declared no conflicts of interest. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
20. 1279P First-line lorlatinib vs crizotinib in Asian patients with ALK+ non-small cell lung cancer (NSCLC): 5-year outcomes from the CROWN study.
- Author
-
Wu, Y-L., Kim, H.R., Soo, R.A., Zhou, Q., Akamatsu, H., Chang, G-C., Chiu, C.H., Hayashi, H., Kim, S-W., Goto, Y., Kato, T., Zhou, J., Lee, V.H.F., Nishio, M., Han, B., Kim, D-W., Lu, S., Polli, A., Martini, J-F., and Mok, T.S.K.
- Subjects
- *
NON-small-cell lung carcinoma , *ASIANS , *CRIZOTINIB - Published
- 2024
- Full Text
- View/download PDF
21. 102O Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1–positive locally advanced/metastatic NSCLC.
- Author
-
Mok, T S K, Wu, Y-L, Kudaba, I, Kowalski, D M, Cho, B C, Turna, H Z, Castro, G de, Srimuninnimit, V, Laktionov, K K, Bondarenko, I, Kubota, K, Caglevic, C, Karaszewska, B, Dang, T, Yin, L, Penrod, J, and Lopes, G
- Subjects
- *
PEMBROLIZUMAB , *NON-small-cell lung carcinoma , *CANCER chemotherapy , *MEDICAL sciences - Published
- 2019
- Full Text
- View/download PDF
22. LBA1IMpower133: Primary efficacy and safety + CNS-related adverse events in a phase I/III study of first-line (1L) atezolizumab + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC).
- Author
-
Mok, T S K, Reck, M, Horn, L, Lam, S, Shames, D S, Liu, J, Kabbinavar, F, Lin, W, Sandler, A, and Liu, S V
- Subjects
- *
HEMATOMA - Published
- 2018
- Full Text
- View/download PDF
23. LBA9IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations.
- Author
-
Mok, T S K, Socinski, M A, Reck, M, Jotte, R M, Lim, D W-T, Cappuzzo, F, Orlandi, F J, Stroyakovskiy, D, Nogami, N, and Rodríguez-Abreu, D
- Subjects
- *
ONCOLOGISTS , *DELETION mutation , *ADVISORY boards - Published
- 2018
- Full Text
- View/download PDF
24. Being molecular in the molecular age.
- Author
-
Raghupathy, R. and Mok, T.
- Subjects
- *
ONCOLOGY , *CANCER - Published
- 2016
- Full Text
- View/download PDF
25. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.
- Author
-
Gadgeel, S, Peters, S, Mok, T, Shaw, A T, Kim, D W, Ou, S I, Pérol, M, Wrona, A, Novello, S, Rosell, R, Zeaiter, A, Liu, T, Nüesch, E, Balas, B, and Camidge, D R
- Subjects
- *
ANAPLASTIC lymphoma kinase , *CRIZOTINIB , *NON-small-cell lung carcinoma , *CLINICAL trial registries , *CENTRAL nervous system - Abstract
Background The phase III ALEX study in patients with treatment-naive advanced anaplastic lymphoma kinase mutation-positive (ALK +) non-small-cell lung cancer (NSCLC) met its primary end point of improved progression-free survival (PFS) with alectinib versus crizotinib. Here, we present detailed central nervous system (CNS) efficacy data from ALEX. Patients and methods Overall, 303 patients aged ≥18 years underwent 1:1 randomization to receive twice-daily doses of alectinib 600 mg or crizotinib 250 mg. Brain imaging was conducted in all patients at baseline and every subsequent 8 weeks. End points (analyzed by subgroup: patients with/without baseline CNS metastases; patients with/without prior radiotherapy) included PFS, CNS objective response rate (ORR), and time to CNS progression. Results In total, 122 patients had Independent Review Committee-assessed baseline CNS metastases (alectinib, n = 64; crizotinib, n = 58), 43 had measurable lesions (alectinib, n = 21; crizotinib, n = 22), and 46 had received prior radiotherapy (alectinib, n = 25; crizotinib, n = 21). Investigator-assessed PFS with alectinib was consistent between patients with baseline CNS metastases [hazard ratio (HR) 0.40, 95% confidence interval (CI): 0.25–0.64] and those without (HR 0.51, 95% CI: 0.33–0.80, P interaction = 0.36). Similar results were seen in patients regardless of prior radiotherapy. Time to CNS progression was significantly longer with alectinib versus crizotinib and comparable between patients with and without baseline CNS metastases (P < 0.0001). CNS ORR was 85.7% with alectinib versus 71.4% with crizotinib in patients who received prior radiotherapy and 78.6% versus 40.0%, respectively, in those who had not. Conclusion Alectinib demonstrated superior CNS activity and significantly delayed CNS progression versus crizotinib in patients with previously untreated, advanced ALK + NSCLC, irrespective of prior CNS disease or radiotherapy. Clinical trial registration ClinicalTrials.gov NCT02075840 [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
26. LBA57 Adagrasib (ADA) vs docetaxel (DOCE) in patients (pts) with KRASG12C-mutated advanced NSCLC and baseline brain metastases (BM): Results from KRYSTAL-12.
- Author
-
Barlesi, F., Yao, W., Duruisseaux, M., Doucet, L., Shi, J., Juan Vidal, O.J., Kim, Y-C., García Campelo, M.R., Azkárate Martínez, A., Lu, S., Jotte, R., Felip, E., Lo Russo, G., Reck, M., Zhang, Y., Hu, N., Michenzie, M.F., and Mok, T.S.K.
- Subjects
- *
DOCETAXEL , *NON-small-cell lung carcinoma - Published
- 2024
- Full Text
- View/download PDF
27. 1394TiP KRYSTAL-7: A phase III study of first-line adagrasib plus pembrolizumab versus pembrolizumab alone in patients with advanced NSCLC with KRASG12C mutation.
- Author
-
Garassino, M.C., Jänne, P.A., Barlesi, F., Spira, A.I., Mok, T.S.K., Hochmair, M., O'Byrne, K.J., Felip, E., Kim, S-W., Cappuzzo, F., Naidoo, J., Safadi, M., Wamil, B., He, J., and Reck, M.
- Subjects
- *
PEMBROLIZUMAB , *NON-small-cell lung carcinoma - Published
- 2024
- Full Text
- View/download PDF
28. Testing for COVID-19 in lung cancer patients.
- Author
-
Passaro, A., Peters, S., Mok, T.S.K., Attili, I., Mitsudomi, T., and de Marinis, F.
- Subjects
- *
LUNG cancer , *CANCER patients , *CORONAVIRUS diseases , *MEDICAL screening , *DIAGNOSIS - Published
- 2020
- Full Text
- View/download PDF
29. Overview of current systemic management of EGFR-mutant NSCLC.
- Author
-
Hsu, W -H, Yang, J C -H, Mok, T S, and Loong, H H
- Subjects
- *
NON-small-cell lung carcinoma , *EPIDERMAL growth factor receptors , *GENETIC mutation , *PROTEIN-tyrosine kinase inhibitors , *CANCER chemotherapy - Abstract
Front-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy is the standard of care for lung cancer patients with sensitising EGFR mutations (exon 19 deletion or L858R mutation). Several phase III studies have demonstrated the superiority of gefitinib, erlotinib (first generation of TKIs) or afatinib (second generation) to chemotherapy in progression-free survival and response rates. Drug-related toxicities, such as diarrhoea, acneiform skin rash, mucositis, and paronychia, are frequently encountered in patients who receive EGFR TKIs. Other rare side-effects, such as hepatic impairment and interstitial lung disease, should be identified early and managed carefully. Patients with uncommon EGFR mutations, such as G719X, S768I, and L861Q, may require special selection of EGFR TKIs. The combination of erlotinib plus bevacizumab has been accepted in certain parts of the world as an alternative front-line treatment. This review article summarizes the studies leading to the establishment of EGFR TKIs in EGFR-mutant lung cancer patients. The side-effect profiles of the current EGFR TKIs in these large trials are listed, and the management of uncommon EGFR mutations is discussed. Finally, the potential role of combination front-line treatment is discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
30. Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer).
- Author
-
Nokihara, H., Lu, S., Mok, T. S. K., Nakagawa, K., Yamamoto, N., Shi, Y. K., Zhang, L., Soo, R. A., Yang, J. C., Sugawara, S., Nishio, M., Takahashi, T., Goto, K., Chang, J., Maemondo, M., Ichinose, Y., Cheng, Y., Lim, W. T., Morita, S., and Tamura, T.
- Subjects
- *
RANDOMIZED controlled trials , *DOCETAXEL , *NON-small-cell lung carcinoma , *CANCER chemotherapy , *IMMUNOTHERAPY , *DRUG side effects , *NAUSEA , *DIARRHEA - Abstract
Background: Chemotherapy remains a viable option for the management of advanced non-small-cell lung cancer (NSCLC) despite recent advances in molecular targeted therapy and immunotherapy. We evaluated the efficacy of oral 5-fluorouracil-based S-1 as second- or third-line therapy compared with standard docetaxel therapy in patients with advanced NSCLC. Patients and methods: Patients with advanced NSCLC previously treated with ≥ 1 platinum-based therapy were randomized 1 : 1 to docetaxel (60 mg/m² in Japan, 75 mg/m² at all other study sites; day 1 in a 3-week cycle) or S-1 (80-120 mg/day, depending on body surface area; days 1-28 in a 6-week cycle). The primary endpoint was overall survival. The non-inferiority margin was a hazard ratio (HR) of 1.2. Results: A total of 1154 patients (577 in each arm) were enrolled, with balanced patient characteristics between the two arms. Median overall survival was 12.75 and 12.52 months in the S-1 and docetaxel arms, respectively [HR 0.945; 95% confidence interval (CI) 0.833-1.073; P=0.3818]. The upper limit of 95% CI of HR fell below 1.2, confirming non-inferiority of S-1 to docetaxel. Difference in progression-free survival between treatments was not significant (HR 1.033; 95% CI 0.913-1.168; P=0.6080). Response rate was 8.3% and 9.9% in the S-1 and docetaxel arms, respectively. Significant improvement was observed in the EORTC QLQ-C30 global health status over time points in the S-1 arm. The most common adverse drug reactions were decreased appetite (50.4%), nausea (36.4%), and diarrhea (35.9%) in the S-1 arm, and neutropenia (54.8%), leukocytopenia (43.9%), and alopecia (46.6%) in the docetaxel arm. Conclusion: S-1 is equally as efficacious as docetaxel and offers a treatment option for patients with previously treated advanced NSCLC. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
31. O1–138PHASE 3 RANDOMIZED STUDY (ARCHER 1050) OF 1ST-LINE DACOMITINIB VS GEFITINIB FOR ADVANCED NSCLC WITH EGFR MUTATION(S).
- Author
-
Mok, T. S. K., Nakagawa, K., Rosell, R., Wu, Y.-l., Trygstad, C., Capizzi, R., DeBenedetto, R., Goldberg, Z., Wang, T., and Antic, V.
- Subjects
- *
RANDOMIZED controlled trials , *EPIDERMAL growth factor receptors , *PROTEIN-tyrosine kinases , *GEFITINIB , *ERLOTINIB , *DRUG efficacy , *BLIND experiment - Published
- 2013
- Full Text
- View/download PDF
32. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
- Author
-
Hendriks, L.E., Kerr, K.M., Menis, J., Mok, T.S., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E.F., Solomon, B.J., Veronesi, G., and Reck, M.
- Subjects
- *
NON-small-cell lung carcinoma , *METASTASIS - Abstract
• This ESMO Clinical Practice Guideline provides key recommendations and algorithms for managing non-oncogene-addicted mNSCLC. • ESMO-MCBS scores are given to describe the levels of evidence for treatment choices. • ESCAT scores are given to describe the evidence level for genomic alterations as biomarkers for using targeted therapies. • Recommendations are based on available scientific data and the authors' collective expert opinion. • In clinical practice, all recommendations provided need to be discussed with patients in a shared decision-making approach. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
33. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
- Author
-
Hendriks, L.E., Kerr, K.M., Menis, J., Mok, T.S., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E.F., Solomon, B.J., Veronesi, G., and Reck, M.
- Subjects
- *
NON-small-cell lung carcinoma , *METASTASIS - Abstract
• This ESMO Clinical Practice Guideline provides key recommendations and algorithms for managing oncogene-addicted mNSCLC. • ESMO-MCBS scores are given to describe the levels of evidence for treatment choices. • ESCAT scores are given to describe the evidence level for genomic alterations as biomarkers for using targeted therapies. • Recommendations are based on available scientific data and the authors' collective expert opinion. • In clinical practice, all recommendations provided need to be discussed with patients in a shared decision-making approach. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
34. A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity.
- Author
-
TSK Mok, W Yeo, PJ Johnson, P Hui, WM Ho, KC Lam, M Xu, K Chak, A Chan, H Wong, F Mo, and B Zee
- Subjects
- *
HERBAL medicine , *CANCER patients , *MEDICAL experimentation on humans , *CLINICAL trials , *PHARMACOLOGY - Abstract
Background: Chinese herbal medicine (CHM) is a common complementary therapy used by patients with cancer for reduction of chemotherapy-induced toxic effects. This study applied the highest standard of clinical trial methodology to examine the role of CHM in reducing chemotherapy-induced toxicity, while maintaining a tailored approach to therapy. Patients and methods: Patients with early-stage breast or colon cancer who required postoperative adjuvant chemotherapy were eligible for the study. Enrolled patients were randomly assigned to one of three Chinese herbalists who evaluated and prescribed a combination of single-item packaged herbal extract granules. Patients received either CHM or placebo packages with a corresponding serial number. The placebo package contained nontherapeutic herbs with an artificial smell and taste similar to a typical herbal tea. The primary end points were hematologic and non-hematologic toxicity according to the National Cancer Institute Common Toxicity Criteria Version 2. Results: One hundred and twenty patients were accrued at the time of premature study termination. Patient characteristics of the two groups were similar. The incidence of grade 3/4 anemia, leukopenia, neutropenia, and thrombocytopenia for the CHM and placebo groups were 5.4%, 47.3%, 52.7%, and 1.8% and 1.8%, 32.2%, 44.7%, and 3.6%, respectively (P = 0.27, 0.37, 0.63, and 0.13, respectively). Incidence of grade 2 nausea was the only non-hematologic toxicity that was significantly reduced in the CHM group (14.6% versus 35.7%, P = 0.04). Conclusions: Traditional CHM does not reduce the hematologic toxicity associated with chemotherapy. CHM, however, does have a significant impact on control of nausea. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
35. 1913P Five year results of transbronchial microwave ablation of lung malignancies with electromagnetic navigation guidance.
- Author
-
Chan, J.W.Y., Chang, A., Siu, I., Lau, R., Ngai, J., Chu, C.M., Mok, T.S.K., and Ng, C.
- Subjects
- *
LUNGS , *MICROWAVES , *NAVIGATION - Published
- 2024
- Full Text
- View/download PDF
36. 1153P Preclinical characterization of MC339: A novel radiotherapeutic agent for DLL3 expressing cancers.
- Author
-
Savinainen, A., Wu, L., Bruton, T., Chonkar, A., Cupido, J., Dearling, J., Huang, C., Lee, K., Ma, Z., Mok, H., Nabi, K., Salih, A., Sutton, A., Tavera, L., Wan, M., Wang, Z., Xu, X., Xu, J., Zidell, A., and Ricardo, A.
- Published
- 2024
- Full Text
- View/download PDF
37. 615MO Phase I/II study of D3S-001, a second generation KRAS G12C inhibitor in advanced/metastatic solid tumors with KRAS G12C mutations.
- Author
-
Cho, B.C., Lu, S., Lee, M.A., Song, Z., Park, J.J.W., Lim, S.M., Li, Z., Zhao, J., Richardson, G., Zhang, Y., Zhang, J., Liu, A., Chen, C., Wang, J., Chen, J., Wang, A., Chen, Z.G., Mok, T.S.K., and Johnson, M.L.
- Subjects
- *
RAS oncogenes , *METASTASIS , *TUMORS - Published
- 2024
- Full Text
- View/download PDF
38. 367P Detection of epidermal growth factor receptor mutations (EGFR-mut) from cell-free DNA in pleural effusion (PE-DNA) of patients with non-small cell lung cancer (NSCLC).
- Author
-
Lee, K.W.C., Lau, Y-M., Mok, T., Chan, V.W.Y., Li, S.C., Chan, O.S.H., Kwong, T.C., Lo, P.Y., and Gai, W.
- Subjects
- *
CELL-free DNA , *NON-small-cell lung carcinoma , *EPIDERMAL growth factor receptor genetics - Published
- 2020
- Full Text
- View/download PDF
39. 1781MO IMpower133: Characterisation of long-term survivors treated first-line with chemotherapy ± atezolizumab in extensive-stage small cell lung cancer.
- Author
-
Liu, S.V., Horn, L., Mok, T., Mansfield, A., De Boer, R., Losonczy, G., Sugawara, S., Dziadziuszko, R., Krzakowski, M., Smolin, A., Hochmair, M.J., Garassino, M.C., Lam, S., McCleland, M., Cardona, A., Morris, S., and Reck, M.
- Subjects
- *
SMALL cell lung cancer , *ATEZOLIZUMAB , *CANCER chemotherapy - Published
- 2020
- Full Text
- View/download PDF
40. Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer.
- Author
-
Schoenfeld, A.J., Antonia, S.J., Awad, M.M., Felip, E., Gainor, J., Gettinger, S.N., Hodi, F.S., Johnson, M.L., Leighl, N.B., Lovly, C.M., Mok, T., Perol, M., Reck, M., Solomon, B., Soria, J.-C., Tan, D.S.W., Peters, S., and Hellmann, M.D.
- Subjects
- *
NON-small-cell lung carcinoma , *IMMUNOTHERAPY , *DISEASE progression , *DEFINITIONS - Abstract
Acquired resistance (AR) to programmed cell death protein 1/programmed death-ligand 1 [PD-(L)1] blockade is frequent in non-small-cell lung cancer (NSCLC), occurring in a majority of initial responders. Patients with AR may have unique properties of persistent antitumor immunity that could be re-harnessed by investigational immunotherapies. The absence of a consistent clinical definition of AR to PD-(L)1 blockade and lack of uniform criteria for ensuing enrollment in clinical trials remains a major barrier to progress; such clinical definitions have advanced biologic and therapeutic discovery. We examine the considerations and potential controversies in developing a patient-level definition of AR in NSCLC treated with PD-(L)1 blockade. Taking into account the specifics of NSCLC biology and corresponding treatment strategies, we propose a practical, clinical definition of AR to PD-(L)1 blockade for use in clinical reports and prospective clinical trials. Patients should meet the following criteria: received treatment that includes PD-(L)1 blockade; experienced objective response on PD-(L)1 blockade (inclusion of a subset of stable disease will require future investigation); have progressive disease occurring within 6 months of last anti-PD-(L)1 antibody treatment or rechallenge with anti-PD-(L)1 antibody in patients not exposed to anti-PD-(L)1 in 6 months. • In NSCLC, acquired resistance to immunotherapy is common and poorly understood. • A uniform clinical definition is imperative to further characterize patients and develop a rational approach to overcoming acquired resistance. • The proposed definition seeks to unify language for future reports and clinical trials in NSCLC. • We also highlight specific areas of uncertainty in classification of acquired resistance that require urgent attention and could lead to further refinements in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
41. 507O EXCLAIM-2: Phase III trial of first-line (1L) mobocertinib versus platinum-based chemotherapy in patients (pts) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)+ locally advanced/metastatic NSCLC.
- Author
-
Jänne, P.A., Wang, B-C., Cho, B.C., Zhao, J., Li, J., Hochmair, M.J., Peters, S., Besse, B., Kato, T., Wu, Y-L., Nguyen, D., Lin, J., Vranceanu, F., Lin, M., Fram, R.J., and Mok, T.S.K.
- Subjects
- *
EPIDERMAL growth factor receptors , *CLINICAL trials , *NON-small-cell lung carcinoma , *CANCER chemotherapy , *METASTASIS - Published
- 2023
- Full Text
- View/download PDF
42. 555P Quality of life in patients with stage IV non-small cell lung cancer and the influence of druggable mutations over time: A prospective, territory-wide study in Hong Kong.
- Author
-
Ho, J.C.S., Wong, C.H.L., Fong, K.S.J., Lee, V.H.F., Lim, M.Y., Kam, T.Y., Nyaw, S.F., Kwan, C.K., Mok, F., Lee, A.W.M., and Cheung, K.M.
- Subjects
- *
NON-small-cell lung carcinoma , *EPIDERMAL growth factor receptors , *QUALITY of life - Published
- 2023
- Full Text
- View/download PDF
43. 528P Socioeconomic determinants of access to standard-of-care treatments in advanced and metastatic NSCLC in Hong Kong: A territory-wide study.
- Author
-
Cheung, K.M., Wong, C.H.L., Chow, J.C.H., Bao, K.K.H., Fong, K.S.J., Lee, V.H.F., Lim, M.Y., Kam, T.Y., Nyaw, S.F., Kwan, C.K., Mok, F., Lee, A.W.M., and Ho, J.C.S.
- Subjects
- *
SOCIOECONOMIC factors , *NON-small-cell lung carcinoma , *METASTASIS - Published
- 2023
- Full Text
- View/download PDF
44. 162P Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update.
- Author
-
Chan, L.L., Chan, A.W.H., Ngai, A.K.H., Mo, F., Mok, K., and Chan, S.L.
- Subjects
- *
HEPATOCELLULAR carcinoma , *SURGERY - Published
- 2023
- Full Text
- View/download PDF
45. 104O IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations.
- Author
-
Reck, M, Jotte, R, Mok, T S K, Lim, D W-T, Cappuzzo, F, Orlandi, F, Stroyakovskiy, D, Nogami, N, Rodríguez-Abreu, D, Moro-Sibilot, D, Thomas, C A, Barlesi, F, Finley, G, Nishio, M, Lee, A, Shankar, G, Yu, W, and Socinski, M A
- Subjects
- *
MEDICAL sciences , *RESEARCH grants , *CANCER hospitals , *PUBLIC hospitals , *ONCOLOGISTS - Published
- 2019
- Full Text
- View/download PDF
46. How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer.
- Author
-
Peters, S, Reck, M, Smit, E F, Mok, T, and Hellmann, M D
- Subjects
- *
NON-small-cell lung carcinoma , *THERAPEUTICS , *SMALL cell lung cancer , *PULMONARY fibrosis , *IMMUNOTHERAPY - Published
- 2019
- Full Text
- View/download PDF
47. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
- Author
-
Planchard, D, Popat, S, Kerr, K, Novello, S, Smit, E F, Faivre-Finn, C, Mok, T S, Reck, M, Schil, P E Van, Hellmann, M D, and Peters, S
- Published
- 2019
- Full Text
- View/download PDF
48. 362P Intracranial activity of dacomitinib in treatment naïve advanced EGFR mutated non-small cell lung cancer (NSCLC): Prespecified subgroup analysis of the ATORG-003 trial.
- Author
-
Tan, A., Kim, D-W., Baisamut (Reungwetwattana), T., Yueh Ni, L., Ho, G.F., Tho, L.M., Prasongsook, N., Lee, S., Mok, T.S.K., Tan, D.S.W., and Loong, H.H.F.
- Subjects
- *
NON-small-cell lung carcinoma , *EPIDERMAL growth factor receptors , *SUBGROUP analysis (Experimental design) - Published
- 2022
- Full Text
- View/download PDF
49. 326P Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: Overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y).
- Author
-
Cho, B.C., Luft, A., Alatorre Alexander, J.A., Lucien Geater, S., Laktionov, K., Sang-We, K., Ursol, G., Hussein, M., Lim Farah, L., Yang, C.T., Araujo, L.H., Saito, H., Reinmuth, N., Lai, Z., Mann, H., Shi, X., Peters, S., Garon, E.B., Mok, T.S.K., and Johnson, M.L.
- Subjects
- *
OVERALL survival , *NON-small-cell lung carcinoma , *CANCER chemotherapy , *METASTASIS - Published
- 2022
- Full Text
- View/download PDF
50. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
- Author
-
Planchard, D, Popat, S, Kerr, K, Novello, S, Smit, E F, Faivre-Finn, C, Mok, T S, Reck, M, Schil, P E Van, and Hellmann, M D
- Subjects
- *
NON-small-cell lung carcinoma , *SMALL cell lung cancer , *MOLECULAR biology , *METASTASIS , *TOBACCO & cancer - Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.